Apricus Biosciences Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Mirror Image	9/10/2015 10:20:06 AM
	Read Replies (2) of 2026

Well - I was wrong about paying nothing upfront. We paid $1 Million upfront and will pay $1.5 Million in a Regulatory Milestone. Vitaros U.S. Deal Summary - Apricus is responsible for all Vitaros development and regulatory efforts in the United States - Allergan retains a one-time opt-in right upon FDA acceptance of an NDA to assume all future marketing and selling activities - Apricus paid Allergan $1 million upfront and there is a future $1.5 million regulatory milestone payable to Allergan -If Allergan elects to opt-in, Apricus may receive up to a total of $25 million in upfront and potential launch milestones, plus a double-digit royalty - If Allergan elects to not opt-in, Apricus may commercialize Vitaros itself and will pay Allergan a double-digit royalty - Allergan retains the right to launch a future AG under a profit share structure with Apricus

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next